Scholar Rock Holding Corporation (SRRK) 10-Year Financial Performance & Capital Metrics

SRRK • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutScholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.Show more

Revenue $0
EBITDA -$250M -48.5%
Net Income -$246M -48.6%
EPS (Diluted) -2.47 -24.1%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -82.95% -21.4%
ROIC -85.72% -37.3%
Debt/Equity 0.18 -35.6%
Interest Coverage -36.87

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 84 (top 16%)
✓Trading near 52-week high

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Shares diluted 31.4% in last year
✗Expensive at 12.6x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-56.41%

EPS CAGR

10Y-

5Y-

3Y-

TTM-30.89%

ROCE

10Y Avg-50.1%

5Y Avg-50.95%

3Y Avg-58.76%

Latest-71.38%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	379K	0	0	20.49M	15.4M	18.82M	33.19M	0	0
Revenue Growth %	-	-1%	-	-	-0.25%	0.22%	0.76%	-1%	-
Cost of Goods Sold+	12.48M	669K	807K	54.22M	74.06M	108.47M	123.04M	2.84M	1.94M
COGS % of Revenue	32.92%	-	-	2.65%	4.81%	5.76%	3.71%	-	-
Gross Profit+	-12.1M	-669K	-807K	-33.73M	-58.66M	-89.65M	-89.85M	-2.84M	-1.94M
Gross Margin %	-31.92%	-	-	-1.65%	-3.81%	-4.76%	-2.71%	-	-
Gross Profit Growth %	-	0.94%	-0.21%	-40.79%	-0.74%	-0.53%	-0%	0.97%	0.32%
Operating Expenses+	16.59M	25.03M	50.69M	20.82M	28.22M	40.27M	44.52M	168.45M	250.12M
OpEx % of Revenue	43.77%	-	-	1.02%	1.83%	2.14%	1.34%	-	-
Selling, General & Admin	4.11M	5.08M	14.38M	20.82M	28.22M	40.27M	42.62M	49.4M	67.5M
SG&A % of Revenue	10.85%	-	-	1.02%	1.83%	2.14%	1.28%	-	-
Research & Development	12.48M	19.94M	36.31M	54.22M	74.06M	108.47M	124.44M	119.06M	182.61M
R&D % of Revenue	32.92%	-	-	2.65%	4.81%	5.76%	3.75%	-	-
Other Operating Expenses	22K	-10K	-56K	-54.22M	-74.06M	-108.47M	-122.54M	0	0
Operating Income+	-16.21M	-25.03M	-50.69M	-54.54M	-86.88M	-129.92M	-134.37M	-171.29M	-252.05M
Operating Margin %	-42.77%	-	-	-2.66%	-5.64%	-6.9%	-4.05%	-	-
Operating Income Growth %	-	-0.54%	-1.03%	-0.08%	-0.59%	-0.5%	-0.03%	-0.27%	-0.47%
EBITDA+	-15.63M	-24.36M	-49.88M	-53.24M	-85.39M	-127.29M	-131.38M	-168.45M	-250.12M
EBITDA Margin %	-41.25%	-	-	-2.6%	-5.54%	-6.77%	-3.96%	-	-
EBITDA Growth %	-	-0.56%	-1.05%	-0.07%	-0.6%	-0.49%	-0.03%	-0.28%	-0.48%
D&A (Non-Cash Add-back)	575K	669K	807K	1.3M	1.49M	2.63M	2.99M	2.84M	1.94M
EBIT	-16.21M	-25.03M	-50.69M	-54.54M	-86.88M	-129.92M	-132.47M	-165.79M	-239.46M
Net Interest Income+	-19K	0	0	0	0	0	0	0	5.84M
Interest Income	0	0	1.42M	0	0	0	0	0	12.68M
Interest Expense	19K	0	0	0	0	0	0	0	6.84M
Other Income/Expense	3K	34K	1.37M	3.54M	395K	-1.88M	-132K	5.51M	5.76M
Pretax Income+	-16.21M	-25M	-49.33M	-51M	-86.48M	-131.8M	-134.5M	-165.79M	-246.29M
Pretax Margin %	-42.76%	-	-	-2.49%	-5.61%	-7%	-4.05%	-	-
Income Tax+	19K	-44K	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-16.21M	-25M	-49.33M	-51M	-86.48M	-131.8M	-134.5M	-165.79M	-246.29M
Net Margin %	-42.76%	-	-	-2.49%	-5.61%	-7%	-4.05%	-	-
Net Income Growth %	-	-0.54%	-0.97%	-0.03%	-0.7%	-0.52%	-0.02%	-0.23%	-0.49%
Net Income (Continuing)	-16.21M	-25M	-49.33M	-51M	-86.48M	-131.8M	-134.5M	-165.79M	-246.29M
Discontinued Operations	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.91	-1.40	-3.15	-1.80	-2.77	-3.59	-2.21	-1.99	-2.47
EPS Growth %	-	-0.54%	-1.25%	0.43%	-0.54%	-0.3%	0.38%	0.1%	-0.24%
EPS (Basic)	-0.91	-1.40	-3.15	-1.80	-2.77	-3.59	-2.21	-1.99	-2.47
Diluted Shares Outstanding	17.91M	17.91M	15.66M	27.54M	30.73M	36.71M	59.61M	75.98M	99.84M
Basic Shares Outstanding	17.91M	17.91M	15.66M	27.54M	30.73M	36.71M	59.61M	75.98M	99.84M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	28.5M	59.2M	177.94M	185.17M	344.4M	265.32M	328.02M	288.19M	451.17M
Cash & Short-Term Investments	28.04M	57.96M	175.65M	157.45M	341.03M	252.99M	315.36M	279.94M	437.28M
Cash Only	10.03M	56.46M	115.07M	36.31M	160.36M	212.84M	103.28M	101.86M	177.88M
Short-Term Investments	18M	1.5M	60.58M	121.14M	180.67M	40.16M	212.09M	178.08M	259.4M
Accounts Receivable	0	0	0	25M	0	0	2.73M	1.08M	2.15M
Days Sales Outstanding	-	-	-	445.3	-	-	30.07	-	-
Inventory	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	2.3M	2.72M	0	12.32M	0	0	0
Total Non-Current Assets+	4.29M	2.44M	3.4M	11.21M	43.9M	39.13M	30.14M	22.84M	23.76M
Property, Plant & Equipment	2.43M	2.18M	3.19M	8.62M	40.38M	35.01M	25.93M	16.02M	18.41M
Fixed Asset Turnover	0.16x	-	-	2.38x	0.38x	0.54x	1.28x	-	-
Goodwill	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	4.07M	2.4M
Long-Term Investments	1.5M	205K	205K	2.5M	0	2.5M	0	0	0
Other Non-Current Assets	360K	50K	0	98K	3.52M	1.62M	4.22M	2.75M	2.96M
Total Assets+	32.78M	61.64M	181.34M	196.38M	388.31M	304.44M	358.17M	311.04M	474.92M
Asset Turnover	0.01x	-	-	0.10x	0.04x	0.06x	0.09x	-	-
Asset Growth %	-	0.88%	1.94%	0.08%	0.98%	-0.22%	0.18%	-0.13%	0.53%
Total Current Liabilities+	3.01M	5.02M	31.12M	32.81M	42.56M	64.3M	36.39M	32.74M	46.94M
Accounts Payable	663K	1.36M	3.3M	1.13M	3.41M	4.43M	3.99M	3.46M	10.1M
Days Payables Outstanding	19.4	741.46	1.49K	7.61	16.8	14.92	11.85	444.7	1.9K
Short-Term Debt	647K	641K	424K	1.14M	0	8.98M	0	1.33M	0
Deferred Revenue (Current)	-647K	-641K	1000K	1000K	1000K	1000K	0	0	0
Other Current Liabilities	879K	1.85M	30K	5.25M	15K	3.13M	222K	85K	0
Current Ratio	9.48x	11.78x	5.72x	5.64x	8.09x	4.13x	9.01x	8.80x	9.61x
Quick Ratio	9.48x	11.78x	5.72x	5.64x	8.09x	4.13x	9.01x	8.80x	9.61x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	59.8M	110.14M	43.59M	50.67M	84.97M	68.07M	61.54M	53.08M	59.35M
Long-Term Debt	1.02M	398K	24K	0	24.68M	48.42M	49.74M	48.68M	50.15M
Capital Lease Obligations	0	0	0	4.17M	27.09M	19.65M	11.8M	4.39M	9.21M
Deferred Tax Liabilities	0	0	-42.72M	0	0	0	0	0	0
Other Non-Current Liabilities	58.78M	109.74M	871K	9K	5K	0	0	0	0
Total Liabilities	62.81M	115.16M	74.71M	83.48M	127.53M	132.37M	97.93M	85.82M	106.29M
Total Debt+	1.67M	1.04M	462K	5.3M	57.14M	84.47M	69.4M	61.82M	65.13M
Net Debt	-8.36M	-55.42M	-114.61M	-31M	-103.22M	-128.37M	-33.88M	-40.04M	-112.75M
Debt / Equity	-	-	0.00x	0.05x	0.22x	0.49x	0.27x	0.27x	0.18x
Debt / EBITDA	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-
Interest Coverage	-853.16x	-	-	-	-	-	-	-	-36.87x
Total Equity+	-30.03M	-53.52M	106.62M	112.9M	260.77M	172.07M	260.24M	225.22M	368.63M
Equity Growth %	-	-0.78%	2.99%	0.06%	1.31%	-0.34%	0.51%	-0.13%	0.64%
Book Value per Share	-1.68	-2.99	6.81	4.10	8.48	4.69	4.37	2.96	3.69
Total Shareholders' Equity	-30.03M	-53.52M	106.62M	112.9M	260.77M	172.07M	260.24M	225.22M	368.63M
Common Stock	1.47M	4K	26K	30K	34K	35K	52K	76K	94K
Retained Earnings	-32.53M	-57.52M	-106.85M	-157.85M	-244.33M	-376.13M	-510.63M	-676.42M	-922.72M
Treasury Stock	57.01M	5K	0	0	0	0	0	0	0
Accumulated OCI	-20K	-2K	-8K	37K	-2K	-35K	-884K	92K	160K
Minority Interest	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-15.14M	-21.74M	24.57M	-63.12M	-60.27M	-126.79M	-132.69M	-145.23M	-200.95M
Operating CF Margin %	-39.95%	-	-	-3.08%	-3.91%	-6.74%	-4%	-	-
Operating CF Growth %	-	-0.44%	2.13%	-3.57%	0.05%	-1.1%	-0.05%	-0.09%	-0.38%
Net Income	-16.21M	-25M	-49.33M	-51M	-86.48M	-131.8M	-134.5M	-165.79M	-246.29M
Depreciation & Amortization	575K	669K	807K	1.3M	1.49M	2.63M	2.99M	2.84M	1.94M
Stock-Based Compensation	556K	1.48M	5.21M	7.97M	11.18M	23.15M	27.7M	27.14M	36.63M
Deferred Taxes	-250K	-199K	272K	176K	0	0	0	0	0
Other Non-Cash Items	-162K	-162K	-289K	-401K	2.3M	7.67M	5.51M	1.19M	186K
Working Capital Changes	347K	1.47M	67.9M	-21.16M	11.24M	-28.44M	-34.39M	-10.61M	6.59M
Change in Receivables	380K	0	0	-25M	25M	0	0	0	0
Change in Inventory	-25.61M	0	0	0	0	0	0	0	0
Change in Payables	91K	636K	1.66M	-1.34M	2.1M	1.02M	-251K	-529K	6.63M
Cash from Investing+	-20.32M	17.66M	-60.23M	-62.24M	-63.5M	134.31M	-171.7M	41.14M	-76.06M
Capital Expenditures	-794K	-361K	-1.49M	-3.12M	-4.09M	-5.25M	-1.06M	-71K	-98K
CapEx % of Revenue	2.09%	-	-	0.15%	0.27%	0.28%	0.03%	-	-
Acquisitions	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-
Other Investing	-19.52M	18.03M	-58.74M	8K	0	0	0	13K	0
Cash from Financing+	1M	50.5M	94.27M	48.88M	247.82M	44.95M	194.83M	102.57M	353.03M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-
Other Financing	0	4.28M	94.94M	900K	7.28M	6.87M	492K	4.87M	28.61M
Net Change in Cash	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-15.94M	-22.1M	23.08M	-66.23M	-64.36M	-132.04M	-133.76M	-145.3M	-201.05M
FCF Margin %	-42.04%	-	-	-3.23%	-4.18%	-7.02%	-4.03%	-	-
FCF Growth %	-	-0.39%	2.04%	-3.87%	0.03%	-1.05%	-0.01%	-0.09%	-0.38%
FCF per Share	-0.89	-1.23	1.47	-2.41	-2.09	-3.60	-2.24	-1.91	-2.01
FCF Conversion (FCF/Net Income)	0.93x	0.87x	-0.50x	1.24x	0.70x	0.96x	0.99x	0.88x	0.82x
Interest Paid	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-185.78%	-46.46%	-46.29%	-60.9%	-62.22%	-68.3%	-82.95%
Return on Invested Capital (ROIC)	-	-	-	-110.69%	-54.42%	-96.83%	-74.63%	-62.43%	-85.72%
Gross Margin	-3192.08%	-	-	-164.58%	-380.83%	-476.47%	-270.69%	-	-
Net Margin	-4276.25%	-	-	-248.88%	-561.47%	-700.46%	-405.21%	-	-
Debt / Equity	-	-	0.00x	0.05x	0.22x	0.49x	0.27x	0.27x	0.18x
Interest Coverage	-853.16x	-	-	-	-	-	-	-	-36.87x
FCF Conversion	0.93x	0.87x	-0.50x	1.24x	0.70x	0.96x	0.99x	0.88x	0.82x
Revenue Growth	-	-100%	-	-	-24.83%	22.16%	76.41%	-100%	-

Frequently Asked Questions

Growth & Financials

Scholar Rock Holding Corporation (SRRK) grew revenue by 0.0% over the past year. Growth has been modest.

Scholar Rock Holding Corporation (SRRK) reported a net loss of $353.4M for fiscal year 2024.

Dividend & Returns

Scholar Rock Holding Corporation (SRRK) has a return on equity (ROE) of -82.9%. Negative ROE indicates the company is unprofitable.

Scholar Rock Holding Corporation (SRRK) had negative free cash flow of $274.6M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Scholar Rock Holding Corporation (SRRK) 10-Year Financial Performance & Capital Metrics

SRRK • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

Revenue $0
EBITDA -$250M -48.5%
Net Income -$246M -48.6%
EPS (Diluted) -2.47 -24.1%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -82.95% -21.4%
ROIC -85.72% -37.3%
Debt/Equity 0.18 -35.6%
Interest Coverage -36.87

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 84 (top 16%)
✓Trading near 52-week high

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Shares diluted 31.4% in last year
✗Expensive at 12.6x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-56.41%

EPS CAGR

10Y-

5Y-

3Y-

TTM-30.89%

ROCE

10Y Avg-50.1%

5Y Avg-50.95%

3Y Avg-58.76%

Latest-71.38%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	379K	0	0	20.49M	15.4M	18.82M	33.19M	0	0
Revenue Growth %	-	-1%	-	-	-0.25%	0.22%	0.76%	-1%	-
Cost of Goods Sold+	12.48M	669K	807K	54.22M	74.06M	108.47M	123.04M	2.84M	1.94M
COGS % of Revenue	32.92%	-	-	2.65%	4.81%	5.76%	3.71%	-	-
Gross Profit+	-12.1M	-669K	-807K	-33.73M	-58.66M	-89.65M	-89.85M	-2.84M	-1.94M
Gross Margin %	-31.92%	-	-	-1.65%	-3.81%	-4.76%	-2.71%	-	-
Gross Profit Growth %	-	0.94%	-0.21%	-40.79%	-0.74%	-0.53%	-0%	0.97%	0.32%
Operating Expenses+	16.59M	25.03M	50.69M	20.82M	28.22M	40.27M	44.52M	168.45M	250.12M
OpEx % of Revenue	43.77%	-	-	1.02%	1.83%	2.14%	1.34%	-	-
Selling, General & Admin	4.11M	5.08M	14.38M	20.82M	28.22M	40.27M	42.62M	49.4M	67.5M
SG&A % of Revenue	10.85%	-	-	1.02%	1.83%	2.14%	1.28%	-	-
Research & Development	12.48M	19.94M	36.31M	54.22M	74.06M	108.47M	124.44M	119.06M	182.61M
R&D % of Revenue	32.92%	-	-	2.65%	4.81%	5.76%	3.75%	-	-
Other Operating Expenses	22K	-10K	-56K	-54.22M	-74.06M	-108.47M	-122.54M	0	0
Operating Income+	-16.21M	-25.03M	-50.69M	-54.54M	-86.88M	-129.92M	-134.37M	-171.29M	-252.05M
Operating Margin %	-42.77%	-	-	-2.66%	-5.64%	-6.9%	-4.05%	-	-
Operating Income Growth %	-	-0.54%	-1.03%	-0.08%	-0.59%	-0.5%	-0.03%	-0.27%	-0.47%
EBITDA+	-15.63M	-24.36M	-49.88M	-53.24M	-85.39M	-127.29M	-131.38M	-168.45M	-250.12M
EBITDA Margin %	-41.25%	-	-	-2.6%	-5.54%	-6.77%	-3.96%	-	-
EBITDA Growth %	-	-0.56%	-1.05%	-0.07%	-0.6%	-0.49%	-0.03%	-0.28%	-0.48%
D&A (Non-Cash Add-back)	575K	669K	807K	1.3M	1.49M	2.63M	2.99M	2.84M	1.94M
EBIT	-16.21M	-25.03M	-50.69M	-54.54M	-86.88M	-129.92M	-132.47M	-165.79M	-239.46M
Net Interest Income+	-19K	0	0	0	0	0	0	0	5.84M
Interest Income	0	0	1.42M	0	0	0	0	0	12.68M
Interest Expense	19K	0	0	0	0	0	0	0	6.84M
Other Income/Expense	3K	34K	1.37M	3.54M	395K	-1.88M	-132K	5.51M	5.76M
Pretax Income+	-16.21M	-25M	-49.33M	-51M	-86.48M	-131.8M	-134.5M	-165.79M	-246.29M
Pretax Margin %	-42.76%	-	-	-2.49%	-5.61%	-7%	-4.05%	-	-
Income Tax+	19K	-44K	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-16.21M	-25M	-49.33M	-51M	-86.48M	-131.8M	-134.5M	-165.79M	-246.29M
Net Margin %	-42.76%	-	-	-2.49%	-5.61%	-7%	-4.05%	-	-
Net Income Growth %	-	-0.54%	-0.97%	-0.03%	-0.7%	-0.52%	-0.02%	-0.23%	-0.49%
Net Income (Continuing)	-16.21M	-25M	-49.33M	-51M	-86.48M	-131.8M	-134.5M	-165.79M	-246.29M
Discontinued Operations	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.91	-1.40	-3.15	-1.80	-2.77	-3.59	-2.21	-1.99	-2.47
EPS Growth %	-	-0.54%	-1.25%	0.43%	-0.54%	-0.3%	0.38%	0.1%	-0.24%
EPS (Basic)	-0.91	-1.40	-3.15	-1.80	-2.77	-3.59	-2.21	-1.99	-2.47
Diluted Shares Outstanding	17.91M	17.91M	15.66M	27.54M	30.73M	36.71M	59.61M	75.98M	99.84M
Basic Shares Outstanding	17.91M	17.91M	15.66M	27.54M	30.73M	36.71M	59.61M	75.98M	99.84M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	28.5M	59.2M	177.94M	185.17M	344.4M	265.32M	328.02M	288.19M	451.17M
Cash & Short-Term Investments	28.04M	57.96M	175.65M	157.45M	341.03M	252.99M	315.36M	279.94M	437.28M
Cash Only	10.03M	56.46M	115.07M	36.31M	160.36M	212.84M	103.28M	101.86M	177.88M
Short-Term Investments	18M	1.5M	60.58M	121.14M	180.67M	40.16M	212.09M	178.08M	259.4M
Accounts Receivable	0	0	0	25M	0	0	2.73M	1.08M	2.15M
Days Sales Outstanding	-	-	-	445.3	-	-	30.07	-	-
Inventory	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	2.3M	2.72M	0	12.32M	0	0	0
Total Non-Current Assets+	4.29M	2.44M	3.4M	11.21M	43.9M	39.13M	30.14M	22.84M	23.76M
Property, Plant & Equipment	2.43M	2.18M	3.19M	8.62M	40.38M	35.01M	25.93M	16.02M	18.41M
Fixed Asset Turnover	0.16x	-	-	2.38x	0.38x	0.54x	1.28x	-	-
Goodwill	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	4.07M	2.4M
Long-Term Investments	1.5M	205K	205K	2.5M	0	2.5M	0	0	0
Other Non-Current Assets	360K	50K	0	98K	3.52M	1.62M	4.22M	2.75M	2.96M
Total Assets+	32.78M	61.64M	181.34M	196.38M	388.31M	304.44M	358.17M	311.04M	474.92M
Asset Turnover	0.01x	-	-	0.10x	0.04x	0.06x	0.09x	-	-
Asset Growth %	-	0.88%	1.94%	0.08%	0.98%	-0.22%	0.18%	-0.13%	0.53%
Total Current Liabilities+	3.01M	5.02M	31.12M	32.81M	42.56M	64.3M	36.39M	32.74M	46.94M
Accounts Payable	663K	1.36M	3.3M	1.13M	3.41M	4.43M	3.99M	3.46M	10.1M
Days Payables Outstanding	19.4	741.46	1.49K	7.61	16.8	14.92	11.85	444.7	1.9K
Short-Term Debt	647K	641K	424K	1.14M	0	8.98M	0	1.33M	0
Deferred Revenue (Current)	-647K	-641K	1000K	1000K	1000K	1000K	0	0	0
Other Current Liabilities	879K	1.85M	30K	5.25M	15K	3.13M	222K	85K	0
Current Ratio	9.48x	11.78x	5.72x	5.64x	8.09x	4.13x	9.01x	8.80x	9.61x
Quick Ratio	9.48x	11.78x	5.72x	5.64x	8.09x	4.13x	9.01x	8.80x	9.61x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	59.8M	110.14M	43.59M	50.67M	84.97M	68.07M	61.54M	53.08M	59.35M
Long-Term Debt	1.02M	398K	24K	0	24.68M	48.42M	49.74M	48.68M	50.15M
Capital Lease Obligations	0	0	0	4.17M	27.09M	19.65M	11.8M	4.39M	9.21M
Deferred Tax Liabilities	0	0	-42.72M	0	0	0	0	0	0
Other Non-Current Liabilities	58.78M	109.74M	871K	9K	5K	0	0	0	0
Total Liabilities	62.81M	115.16M	74.71M	83.48M	127.53M	132.37M	97.93M	85.82M	106.29M
Total Debt+	1.67M	1.04M	462K	5.3M	57.14M	84.47M	69.4M	61.82M	65.13M
Net Debt	-8.36M	-55.42M	-114.61M	-31M	-103.22M	-128.37M	-33.88M	-40.04M	-112.75M
Debt / Equity	-	-	0.00x	0.05x	0.22x	0.49x	0.27x	0.27x	0.18x
Debt / EBITDA	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-
Interest Coverage	-853.16x	-	-	-	-	-	-	-	-36.87x
Total Equity+	-30.03M	-53.52M	106.62M	112.9M	260.77M	172.07M	260.24M	225.22M	368.63M
Equity Growth %	-	-0.78%	2.99%	0.06%	1.31%	-0.34%	0.51%	-0.13%	0.64%
Book Value per Share	-1.68	-2.99	6.81	4.10	8.48	4.69	4.37	2.96	3.69
Total Shareholders' Equity	-30.03M	-53.52M	106.62M	112.9M	260.77M	172.07M	260.24M	225.22M	368.63M
Common Stock	1.47M	4K	26K	30K	34K	35K	52K	76K	94K
Retained Earnings	-32.53M	-57.52M	-106.85M	-157.85M	-244.33M	-376.13M	-510.63M	-676.42M	-922.72M
Treasury Stock	57.01M	5K	0	0	0	0	0	0	0
Accumulated OCI	-20K	-2K	-8K	37K	-2K	-35K	-884K	92K	160K
Minority Interest	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-15.14M	-21.74M	24.57M	-63.12M	-60.27M	-126.79M	-132.69M	-145.23M	-200.95M
Operating CF Margin %	-39.95%	-	-	-3.08%	-3.91%	-6.74%	-4%	-	-
Operating CF Growth %	-	-0.44%	2.13%	-3.57%	0.05%	-1.1%	-0.05%	-0.09%	-0.38%
Net Income	-16.21M	-25M	-49.33M	-51M	-86.48M	-131.8M	-134.5M	-165.79M	-246.29M
Depreciation & Amortization	575K	669K	807K	1.3M	1.49M	2.63M	2.99M	2.84M	1.94M
Stock-Based Compensation	556K	1.48M	5.21M	7.97M	11.18M	23.15M	27.7M	27.14M	36.63M
Deferred Taxes	-250K	-199K	272K	176K	0	0	0	0	0
Other Non-Cash Items	-162K	-162K	-289K	-401K	2.3M	7.67M	5.51M	1.19M	186K
Working Capital Changes	347K	1.47M	67.9M	-21.16M	11.24M	-28.44M	-34.39M	-10.61M	6.59M
Change in Receivables	380K	0	0	-25M	25M	0	0	0	0
Change in Inventory	-25.61M	0	0	0	0	0	0	0	0
Change in Payables	91K	636K	1.66M	-1.34M	2.1M	1.02M	-251K	-529K	6.63M
Cash from Investing+	-20.32M	17.66M	-60.23M	-62.24M	-63.5M	134.31M	-171.7M	41.14M	-76.06M
Capital Expenditures	-794K	-361K	-1.49M	-3.12M	-4.09M	-5.25M	-1.06M	-71K	-98K
CapEx % of Revenue	2.09%	-	-	0.15%	0.27%	0.28%	0.03%	-	-
Acquisitions	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-
Other Investing	-19.52M	18.03M	-58.74M	8K	0	0	0	13K	0
Cash from Financing+	1M	50.5M	94.27M	48.88M	247.82M	44.95M	194.83M	102.57M	353.03M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-
Other Financing	0	4.28M	94.94M	900K	7.28M	6.87M	492K	4.87M	28.61M
Net Change in Cash	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-15.94M	-22.1M	23.08M	-66.23M	-64.36M	-132.04M	-133.76M	-145.3M	-201.05M
FCF Margin %	-42.04%	-	-	-3.23%	-4.18%	-7.02%	-4.03%	-	-
FCF Growth %	-	-0.39%	2.04%	-3.87%	0.03%	-1.05%	-0.01%	-0.09%	-0.38%
FCF per Share	-0.89	-1.23	1.47	-2.41	-2.09	-3.60	-2.24	-1.91	-2.01
FCF Conversion (FCF/Net Income)	0.93x	0.87x	-0.50x	1.24x	0.70x	0.96x	0.99x	0.88x	0.82x
Interest Paid	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-185.78%	-46.46%	-46.29%	-60.9%	-62.22%	-68.3%	-82.95%
Return on Invested Capital (ROIC)	-	-	-	-110.69%	-54.42%	-96.83%	-74.63%	-62.43%	-85.72%
Gross Margin	-3192.08%	-	-	-164.58%	-380.83%	-476.47%	-270.69%	-	-
Net Margin	-4276.25%	-	-	-248.88%	-561.47%	-700.46%	-405.21%	-	-
Debt / Equity	-	-	0.00x	0.05x	0.22x	0.49x	0.27x	0.27x	0.18x
Interest Coverage	-853.16x	-	-	-	-	-	-	-	-36.87x
FCF Conversion	0.93x	0.87x	-0.50x	1.24x	0.70x	0.96x	0.99x	0.88x	0.82x
Revenue Growth	-	-100%	-	-	-24.83%	22.16%	76.41%	-100%	-

Frequently Asked Questions

Growth & Financials

Scholar Rock Holding Corporation (SRRK) grew revenue by 0.0% over the past year. Growth has been modest.

Scholar Rock Holding Corporation (SRRK) reported a net loss of $353.4M for fiscal year 2024.

Dividend & Returns

Scholar Rock Holding Corporation (SRRK) has a return on equity (ROE) of -82.9%. Negative ROE indicates the company is unprofitable.

Scholar Rock Holding Corporation (SRRK) had negative free cash flow of $274.6M in fiscal year 2024, likely due to heavy capital investments.